A study evaluating efficacy of Nab paclitaxel and Gemcitabine compared to FOLFIRINOX in patients with metastatic pancreatic cancer

Trial Profile

A study evaluating efficacy of Nab paclitaxel and Gemcitabine compared to FOLFIRINOX in patients with metastatic pancreatic cancer

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Apr 2018

At a glance

  • Drugs Gemcitabine (Primary) ; Paclitaxel (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Adenocarcinoma; Carcinoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Apr 2018 New trial record
    • 03 Apr 2018 Primary end point (Overall Survival) has been met as per the results published in the Investigational New Drugs.
    • 03 Apr 2018 Primary end point (Progression Free Survival) has not been met as per the results published in the Investigational New Drugs.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top